Drug Trial Radar · NCT06351592
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Aug 28, 2024
Primary completion
Mar 21, 2032
Study completion Mar 21, 2032
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Apr 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * The effect the study drug has on specific biomarkers, which are substances in the blood or in the fluid that surrounds the brain and spinal cord, known as Cerebrospinal Fluid (CSF) * How much study drug is in the blood and in the CSF, at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * What effects the study drug has on ALS symptoms
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Interventions
ALN-SODDrug
Administered per the protocol
DiluentOther
Administered per the protocol
Placebo (PB)Drug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SODTime frame: At week 4 and through week 228
- Severity of TEAEs in participants treated with ALN-SODTime frame: At week 4 and through week 228
Locations
22 sites in 9 countries. Site status is shown where the registry gives one.
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Recruiting
Macquarie University
Sydney, New South Wales, Australia · Recruiting
Sunshine Coast University Hospital
Birtinya, Queensland, Australia · Recruiting
KU Leuven
Leuven, Vlaams-Brabant, Belgium · Recruiting
University of Alberta Hospital, Edmonton, Division of Neurology
Edmonton, Alberta, Canada · Recruiting
University Hospital - London Health Sciences Centre
London, Ontario, Canada · Recruiting
Sunnybrook Research Institute
Toronto, Ontario, Canada · Recruiting
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada · Recruiting
Universitaetsklinikum Ulm AoR
Ulm, Baden-Wurttemberg, Germany · Recruiting
Kyoto University Hospital
Kyoto, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Tokushima University Hospital
Tokushima, Tokushima, Japan · Recruiting
Toho University Omori Medical Center
Ōta-ku, Tokyo, Japan · Recruiting
MTZ Clinical Research powered by Pratia
Warsaw, Poland · Recruiting
Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Neurologii
Krakow, Lesser Poland Voivodeship, Poland · Recruiting
Medical University of Silesia
Zabrze, Silesian Voivodeship, Poland · Recruiting
Hanyang University Seoul Hospital
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Noorlands University Hospital-Department of Neurology
Umeå, Noorland, Sweden · Recruiting
Karolinska University Hospital, Karolinska Institutet-ALS Center-Department of Clinical Neuroscience
Huddinge, Stockholm County, Sweden · Recruiting
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.